权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Uncovering compensatory mechanisms in family members with disease causing mutations of pulmonary hypertension

揭示患有导致肺动脉高压突变的疾病的家庭成员的补偿机制

基本信息

批准号：
10460463
负责人：
Mingxia Gu
金额：
$ 24.9万
依托单位：
CINCINNATI CHILDRENS HOSP MED CTR
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-15 至 2023-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10460463
关键词：
Accounting Adhesions Alagille Syndrome BIRC3 gene BMPR2 gene Bioinformatics Biological Assay Biological Sciences Blood Vessels CRISPR/Cas technology Cardiovascular Diseases Cardiovascular system Cell Adhesion Cell Survival Cell physiology Cells Cessation of life ChIP-seq Clinical Clustered Regularly Interspaced Short Palindromic Repeats Collaborations Development Diagnosis Disease Drug Screening Endothelial Cells Endothelium Enhancers Epigenetic Process Extracellular Matrix FDA approved Family Family member Fellowship Financial compensation Foundations Functional disorder Gene Expression Gene Expression Profile Genes Genetic Diseases Genetic Polymorphism Heritability Histones Lead Light Lung MMP3 gene Marfan Syndrome Modeling Molecular Mutation Other Genetics Pathway interactions Patients Penetrance Penetration Peripheral Pharmaceutical Preparations Phase Phenotype Pulmonary Hypertension RNA Research Role Signal Pathway Signal Transduction Signaling Protein Source Symptoms System Tacrolimus Binding Protein 1A Technology Testing Transcript Vascular Diseases Vascular Proliferation Williams Syndrome austin bone morphogenetic protein receptors caveolin 1 differential expression disease-causing mutation drug use screening endothelial dysfunction epigenome genome sequencing high throughput screening improved induced pluripotent stem cell interest loss of function loss of function mutation mutation carrier novel novel therapeutic intervention novel therapeutics p38 Mitogen Activated Protein Kinase personalized medicine precision drugs preservation prevent programs pulmonary arterial hypertension pulmonary vascular remodeling right ventricular failure transcriptome transcriptome sequencing transcriptomics whole genome

项目摘要

Pulmonary arterial hypertension (PAH) in its familial form (FPAH) is a heritable autosomal dominant disorder that, in the majority of patients, results in progressive right heart failure and death within five years of diagnosis. Bone morphogenetic protein receptor (BMPR) 2 haploinsufficiency occurs in over 70% of the FPAH patients, but intriguingly, only 20% of mutation carriers get clinical disease. This proposal aims to uncover the mechanism underlying the reduced penetrance of BMPR2 mutation in causing FPAH using patient-specific induced pluripotent stem cells derived endothelial cells (iPSC-ECs). Understanding the molecular mechanisms underlying the protective phenotype in those BMPR2 mutation carriers without FPAH could lead to novel therapeutic approaches for familial and non-familial forms of PAH as they all share reduced expression or function of BMPR2. These studies also hold the key to understanding penetrance in other genetic conditions related to PAH, such as the caveolin 1 (CAV1) mutation. Studies carried out during Dr. Gu's AHA postdoctoral fellowship utilized iPSC-ECs from three sets of FPAH patients and from their family members with the same BMPR2 mutation but without disease. Dr. Gu uncovered a compensatory p-p38 signaling pathway leading to preserved adhesion and survival of iPSC-ECs from the unaffected mutation carriers. The mechanism accounting for the preserved p-p38 signaling appears to differ among the families. The first aim (K99 phase) of Dr. Gu's proposed studies is to extend the findings described above, through gain and loss of function studies to pursue the mechanism of `carrier compensation'. She will also determine whether correction of the BMPR2 mutation by CRISPR/Cas9 technology restores BMP signaling pathways and EC functions in FPAH iPSC-EC from all three families. The second aim (K99 phase) will determine how the transcriptome and epigenome explain the protective phenotype in the unaffected mutation carriers. RNA-Seq was carried out on iPSC-ECs from all family members (n=11). Seventy-one differentially expressed genes were identified by comparing iPSC-ECs from controls and mutation carriers versus FPAH patients, and four genes of interest have been verified by qPCR. This aim is strengthened by a collaboration with Dr. Michael Snyder's lab, to help relate gene expression changes with alterations in histone marks identified by ChIP-Seq and polymorphisms called by whole genome sequencing. The third aim (R00 phase) will extend studies in Specific Aims 1 and 2 to novel mutations associated with FPAH, such as caveolin1. In the fourth aim (R00 phase), Dr. Gu will establish a high-throughput platform for personalized drug screening using iPSC-ECs as a continuous cell source. These studies will help Dr. Gu to launch a research program that optimizes the use of iPSC-derived vascular cells and integrative `omic' technologies to model vascular disease pathophysiology and to develop personalized treatments using either a bioinformatics' approach or high throughput screening to repurpose FDA approved drugs that activate the protective pathway.

家族型肺动脉高压（PAH）是一种遗传性常染色体显性遗传病

项目成果

期刊论文数量（13）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Hypoplastic left heart syndrome (HLHS): molecular pathogenesis and emerging drug targets for cardiac repair and regeneration.

DOI：
10.1080/14728222.2021.1978069
发表时间：
2021-08
期刊：
Expert opinion on therapeutic targets
影响因子：
5.8
作者：
Bejjani AT;Wary N;Gu M
通讯作者：
Gu M

Capillary cell-type specialization in the alveolus.

DOI：
10.1038/s41586-020-2822-7
发表时间：
2020-10
期刊：
Nature
影响因子：
64.8
作者：
Gillich A;Zhang F;Farmer CG;Travaglini KJ;Tan SY;Gu M;Zhou B;Feinstein JA;Krasnow MA;Metzger RJ
通讯作者：
Metzger RJ

Single-Cell RNA Sequencing (scRNA-seq) in Cardiac Tissue: Applications and Limitations.

心脏组织中的单细胞RNA测序（SCRNA-SEQ）：应用和局限性。